ReviewCurrent atherosclerosis reports2010
Future therapeutic directions in reverse cholesterol transport.
Review in Current atherosclerosis reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin.Journal of the American Heart Association · 2018Trial
- Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis.Journal of atherosclerosis and thrombosis · 2026Observational
- Effect of Probiotics ContainingFoods (Basel, Switzerland) · 2025Review
- Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?Current atherosclerosis reports · 2025Review
- MP Allosterically Activates AMPK to Enhance ABCA1 Stability by Retarding the Calpain-Mediated Degradation Pathway.International journal of molecular sciences · 2023Article
- Sirt6 enhances macrophage lipophagy and improves lipid metabolism disorder by regulating the Wnt1/β-catenin pathway in atherosclerosis.Lipids in health and disease · 2023Article
- Genetic Factors for Coronary Heart Disease and Their Mechanisms: A Meta-Analysis and Comprehensive Review of Common Variants from Genome-Wide Association Studies.Diagnostics (Basel, Switzerland) · 2022Review
- A Systematic Review of Apolipoprotein A-I Mimetic Peptides for Atherosclerosis Therapy via Activation of the Reverse Cholesterol Transport Pathway.ARYA atherosclerosis · 2022Review
- Role of macrophage scavenger receptor MSR1 in the progression of non-alcoholic steatohepatitis.Frontiers in immunology · 2022Review
- Rosmarinic Acid Increases Macrophage Cholesterol Efflux through Regulation of ABCA1 and ABCG1 in Different Mechanisms.International journal of molecular sciences · 2021Article
- Functional Food and Bioactive Compounds on the Modulation of the Functionality of HDL-C: A Narrative Review.Nutrients · 2021Review
- Interactions of Lipid Droplets with the Intracellular Transport Machinery.International journal of molecular sciences · 2021Review
- Antioxidant and anti‑inflammatory mechanisms of action of astaxanthin in cardiovascular diseases (Review).International journal of molecular medicine · 2021Review
- Intravenous Curcumin Mitigates Atherosclerosis Progression in Cholesterol-Fed Rabbits.Advances in experimental medicine and biology · 2021Article
- A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoEBritish journal of pharmacology · 2020Article
- The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.International journal of molecular sciences · 2020Review
- Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease.Advances in experimental medicine and biology · 2020Review
- Subclinical atherosclerosis and its progression are modulated by PLIN2 through a feed-forward loop between LXR and autophagy.Journal of internal medicine · 2019Article
- The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.Scientific reports · 2019Article
- HDL and Reverse Cholesterol Transport.Circulation research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite a robust inverse association between high-density lipoprotein (HDL) cholesterol levels and atherosclerotic cardiovascular disease, the development of new therapies based on pharmacologic enhancement of HDL metabolism has proven challenging. Emerging evidence suggests that static measurement of HDL levels has inherent limitations as a surrogate for overall HDL functionality, particularly with regard to the rate of flux through the macrophage reverse cholesterol transport (RCT) pathway. Recent research has provided important insight into the molecular underpinnings of RCT, the process by which excess cellular cholesterol is effluxed from peripheral tissues and returned to the liver for ultimate intestinal excretion. This review discusses the critical importance and current strategies for quantifying RCT flux. It also highlights therapeutic strategies for augmenting macrophage RCT via three conceptual approaches: 1) improved efflux of cellular cholesterol via targeting the macrophage; 2) enhanced cholesterol efflux acceptor functionality of circulating HDL; and 3) increased hepatic uptake and biliary/intestinal excretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.